Actelion's Tracleer successor clears European hurdle
This article was originally published in Scrip
Executive Summary
Actelion's Tracleer successor Opsumit (macitentan) has been approved by the European Commission for the long-term treatment of pulmonary arterial hypertension (PAH) in the EU.